Canada: Life Sciences, Biotechnology & Nanotechnology

Subscribe

Welcome to the Mondaq Food, Drugs, Healthcare, Life Sciences homepage, here you will find thought leadership articles, podcasts, videos and webinars providing insights covering topics such as Food and Drugs Law, Healthcare, Life Sciences, Biotechnology and Nanotechnology.

La Cour d'appel fédérale confirme qu'il n'est pas nécessaire de tenir compte des demandes de brevets déposées avant la présentation abrégée de drogue nouvelle pour un médicament générique, mais inscrites au registre après

Le 8 août 2025, la Cour d'appel fédérale (CAF) a jugé que la décision du ministre de la Santé d'inscrire le brevet canadien no 2970315 au Registre des brevets 8 jours...

SB

Smart & Biggar

Les tendances observées dans les demandes de brevets relatives aux technologies médicales assistées par l'intelligence artificielle

Les technologies médicales intégrant l'intelligence artificielle (IA) constituent un domaine d'innovation émergent susceptible de révolutionner les soins de santé. Grâce à des techniques telles...

SB

Smart & Biggar

Un programme pilote de l'Ontario ainsi qu'une nouvelle voie de négociation de l'APP pour accélérer l'accès à des traitements novateurs contre le cancer

En octobre 2025, le gouvernement de l'Ontario et l'Alliance pancanadienne pharmaceutique (APP) ont annoncé des initiatives distinctes visant toutes deux à accélérer l'accès des patients...

Canada Healthcare

SB

Smart & Biggar

Le CEPMB publie son Rapport annuel sur les dépenses des régimes publics d'assurance médicaments (2022-2023)

Le 21 octobre 2025, le Conseil d'examen du prix des médicaments brevetés (CEPMB) a annoncé la publication de CompasRX (10e édition)...

Canada Healthcare

SB

Smart & Biggar

Santé Canada publie son Rapport statistique 2024/2025 pour le Règlement sur les médicaments brevetés (avis de conformité), la protection des données et les certificats de protection supplémentaire

SB

Smart & Biggar

L'AMC publie sa stratégie visant l'amélioration de la prescription et de l'utilisation appropriées des médicaments d'ordonnance au Canada

Canada Healthcare

SB

Smart & Biggar

La Cour suprême du Canada a mis en délibéré son jugement dans le cadre de l'appel relatif à la brevetabilité des méthodes de traitement médical

SB

Smart & Biggar

Ontario Moves To Regulate Preferred Pharmacy Networks (PPNs)

Canada Healthcare

F

Fasken

Santé Canada cherche à réduire le fardeau administratif en renforçant la collaboration, l'alignement et la confiance à l'échelle internationale

Canada Healthcare

SB

Smart & Biggar

Huitième anniversaire des modifications majeures apportées au Règlement sur les MB (AC)

SB

Smart & Biggar

Faits saillants du premier semestre 2025 au Canada en matière de la PI en sciences de la vie et de droit règlementaire

SB

Smart & Biggar

Publication de la version définitive des Lignes directrices du CEPMB

Canada Healthcare

SB

Smart & Biggar

L'AMC ouvre une consultation sur la liste provisoire de médicaments pour guider l'élaboration d'une liste nationale de médicaments assurés

Canada Healthcare

SB

Smart & Biggar

Mise à jour sur les instruments médicaux : nouvelles lignes directrices de Santé Canada pour déterminer les types de demandes relatives aux instruments médicaux et publication des rapports sur le rendement de la Direction des instruments médicaux

Canada Healthcare

SB

Smart & Biggar

When CRA Denies Penalty Relief In Major Non-Compliance Cases: Offshore Income And Aggressive Tax Shelters (2020–2025)

RS

Rotfleisch & Samulovitch P.C.

Share Redemption And Share Retraction: Tax Treatment By CRA—plus They Are Useful Tax Planning Tools

RS

Rotfleisch & Samulovitch P.C.

The CRA Issues A New Income Tax Folio On 'Deemed Interest Benefit On Shareholder Loans And Debts': How Is It Treated For Tax Purposes?

RS

Rotfleisch & Samulovitch P.C.

2025 Federal Budget Tax Highlights

CM

Crowe MacKay LLP

Now Hiring? New Job Posting Rules Take Effect In 2026

Canada Employment

WH

Williams HR Law

Rosen Sunshine Newsletter - November 2025

We are honoured to be included in The Globe and Mail's annual Canada's Best Law Firms List, for 2026 in the Healthcare & Life Sciences practice area!

Canada Healthcare

RS

Rosen Sunshine LLP

Streamlined Biosimilar Approvals: What The End Of Biosimilar Phase III Trials Means For Innovative Pharmaceutical Patent Holders

The U.S. Food and Drug Administration (FDA) has released a landmark draft guidance on biosimilar submission requirements (the "draft guidance", link here).

Canada Healthcare

MT

McCarthy Tétrault LLP

Recent Biologics Decisions At Health Canada

In the last few weeks, Health Canada issued several decisions concerning biologics.

Canada Healthcare

GP

Goodwin Procter LLP

Ontario Pilot Program And PCPA New Negotiation Pathway Aim To Expedite Access To Breakthrough Cancer Treatments

The Ontario government and the pan-Canadian Pharmaceutical Alliance (pCPA) announced separate initiatives in October 2025, both aimed to accelerate patient access to breakthrough cancer treatments approved through the Project Orbis pathway.

Canada Healthcare

SB

Smart & Biggar

Santé Canada et l'Agence de la santé publique du Canada publient un rapport sur la réduction du fardeau administratif

Canada Healthcare

BC

Blake, Cassels & Graydon LLP

CDA Releases Strategy To Improve The Appropriate Prescribing And Use Of Prescription Medications In Canada

Canada Healthcare

SB

Smart & Biggar

Health Canada And The Public Health Agency Of Canada Release Report On Cutting Red Tape

Canada Healthcare

BC

Blake, Cassels & Graydon LLP

British Columbia Proposes Legislation To Recoup Vaping-related Health Care Costs

Canada Healthcare

TL

Torys LLP

Growing Protection For Plant Varieties: Changes Coming To Canada's Plant Breeders' Rights Regulations

Canada Healthcare

TL

Torys LLP

Medical Devices Updates: New Health Canada Guidance For Determining Medical Device Application Type And Medical Devices Directorate Performance Reports Released

Canada Healthcare

SB

Smart & Biggar

Health Canada And The Public Health Agency Of Canada Report On Red Tape Reduction Measures

Canada Healthcare

GW

Gowling WLG

Can I Sue A Doctor Or Nurse?

Canada Healthcare

HS

Howie, Sacks & Henry LLP

A New Era: Health Canada Signals Modernization In Policy And Regulatory Reform

Canada Healthcare

BL

Borden Ladner Gervais LLP

Health Canada's Product Safety Pledge: A Model Product Safety Framework For Consumer Products And Cosmetics

Canada Healthcare

BL

Borden Ladner Gervais LLP

Health Canada And The Public Health Agency Of Canada Report On Red Tape Reduction Measures

In July 2025, the federal government issued a directive to federal regulators to examine their internal process and issue a report on where efficiencies can be achieved.

Canada Healthcare

GW

Gowling WLG

Can I Sue A Doctor Or Nurse?

Doctors and nurses in Canada can be sued for medical malpractice (also called medical negligence) if they provide care that falls below the accepted medical standard and that failure causes...

Canada Healthcare

HS

Howie, Sacks & Henry LLP

A New Era: Health Canada Signals Modernization In Policy And Regulatory Reform

On Sept. 8, 2025, Health Canada and the Public Health Agency of Canada published their Report on Red Tape Reduction, outlining their key regulatory modernization initiatives aimed at improving efficiency, transparency and responsiveness within Canada's health system.

Canada Healthcare

BL

Borden Ladner Gervais LLP

Health Canada's Product Safety Pledge: A Model Product Safety Framework For Consumer Products And Cosmetics

On August 25, 2025, Health Canada released its first annual report (the Report) summarizing anonymized self assessment data received in respect of the reporting period beginning September 29, 2023, and ending September 28, 2024, from signatories to the Canadian Product Safety Pledge for Consumer Products and Cosmetics.

Canada Healthcare

BL

Borden Ladner Gervais LLP

Canada's Plan Of Priorities Includes Several Nanoscale Materials

Canada Healthcare

BC

Bergeson & Campbell

Les nouvelles lignes directrices du CEPMB sont enfin disponibles

Le 30 juin, le Conseil d'examen du prix des médicaments brevetés (le « CEPMB ») a publié les Lignes directrices pour le personnel du CEPMB...

Canada Healthcare

FF

Fasken (French)

The Court Grants An Appeal In Favour Of Psychedelic Assisted Psychotherapy – Toth v. Canada, 2025 FCA 119

A ruling from the Federal Court of Canada has resulted in an appeal of prior government refusals to permit access to psilocybin in connection with psilocybin assisted psychotherapy ("PSAP").

Canada Healthcare

ML

McMillan LLP

2025 Mid-year Highlights In Canadian Life Sciences IP And Regulatory Law

In the first half of 2025, the Rx IP Update team reported on a number of developments in Canadian life sciences IP and regulatory law. Below are our top stories.

Canada Healthcare

SB

Smart & Biggar

Important New Procedural Guidelines From The PMPRB

The Patented Medicine Prices Review Board (PMPRB) is a Canadian federal agency that regulates the prices of patented medicines in Canada.

AM

Aird & McBurney LP

Final Guidelines From Canada's PMPRB: The New Era Begins

TL

Torys LLP

Finalized PMPRB Guidelines Published

SB

Smart & Biggar

At Long Last: The New PMPRB Guidelines Are Here

Worldwide Healthcare

F

Fasken

CDA Opens Consultation On Proposed List Of Drugs To Inform Development Of National Formulary

Canada Healthcare

SB

Smart & Biggar

Closing The Value Gap Using Earnouts In Life Sciences M&A

Canada Healthcare

AB

Aird & Berlis LLP

Health Canada Must Redetermine Exemption Requests For Psilocybin (Magic Mushroom)-Assisted Psychotherapy Training

Canada Healthcare

SB

Smart & Biggar

Update On Biosimilars In Canada – June 2025

Canada Healthcare

SB

Smart & Biggar

Updated PMPRB Guidelines Expected In Summer 2025 And NPDUIS Releases Ninth Edition Of The Meds Entry Watch Report

Canada Healthcare

SB

Smart & Biggar

La nouvelle ébauche de la Ligne directrice de Santé Canada sur les médicaments biologiques biosimilaires

Canada Healthcare

FF

Fasken (French)

Health Canada Consultation On Revised Biosimilar Guidance: No Requirement For Comparative Clinical Efficacy And Safety Trials

Canada Healthcare

SB

Smart & Biggar

Biosimilar Update: Health Canada Reconsiders Requirement For Comparative Clinical Trials

Canada Healthcare

MT

McCarthy Tétrault LLP

Apotex Not Entitled To Damages For Delayed Generic Drug Launch

TS

Tierney Stauffer LLP

CDA Update: New Five-Year Strategic Plan And Position Statement On Using AI In Health Technology Assessments

Canada Healthcare

SB

Smart & Biggar

Les incidences du projet de loi 83 sur les médecins et le système de santé du Québec

Canada Healthcare

FF

Fasken (French)

2024 Deal Points Report: Venture Capital Financings

Canada Commercial

OH

Osler, Hoskin & Harcourt LLP

See more

Latest Videos

See more

Lois canadiennes, américaines, britanniques et européennes entourant l'Internet des objets (Video)

BL

Borden Ladner Gervais LLP

The Legal Steps To Startups: Health & Life Science (Video)

PM

Parlee McLaws

How To Protect Ideas In The Booming Life Sciences Sector (Video)

GW

Gowling WLG

Financing Life Sciences On Both Sides Of The Border (Video)

TL

Torys LLP

Le Secteur De La Santé Au Canada Après La COVID-19 : Perspectives Juridiques, Médicales Et Commerciales (vidéos)

SE

Stikeman Elliott LLP

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More